Acne Vulgaris Clinical Trial
Official title:
Comparison of Malassezia Spp Proportions in Inflammatory and Non Inflammatory Facial Acne Vulgaris Lesions
Verified date | April 2020 |
Source | Indonesia University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
Acne vulgaris (AV) is a common inflammatory condition involving pilosebaceous unit. The
pathogenesis of acne is multifactorial and skin microbiome is considered to be one of the key
factors that aggravate inflammation. Malassezia spp is normal flora on the skin and several
studies have reported its corelation with inflammatory AV lesion.
Malassezia have higher lipase activity compared to Propionibacterium acnes which triggers an
increase in free fatty acid and glycerol, the chemotactic factors towards neutrophils and
inducing inflammation in AV. Malassezia folliculitis (MF) is sometimes confused with and may
present together with AV. Pruritus usually presents in MF but some studies also reported
itching as common symptom in AV.
The objectives of this study were to identify the presence and the distribution of Malassezia
spp. in facial AV lesions, to compare the distribution of Malassezia spp. between
inflammatory and non-inflammatory lesions and to identify the association between Malassezia
spp in acne lesions and pruritus symptom.
Status | Completed |
Enrollment | 120 |
Est. completion date | December 30, 2018 |
Est. primary completion date | November 30, 2018 |
Accepts healthy volunteers | |
Gender | All |
Age group | 15 Years to 49 Years |
Eligibility |
Inclusion Criteria: - Subjects with age of 15-49 years with AV and the presence of at least four inflammatory and four non-inflammatory lesions Exclusion Criteria: - Subjects with prior topical retinoid acid or topical antifungal medication within the past two weeks, systemic antibiotic or antifungal use within the past month, and corticosteroid use within the past six months |
Country | Name | City | State |
---|---|---|---|
Indonesia | Dr. Cipto Mangunkusumo Hospital, Jakarta, Indonesia | Jakarta Pusat | DKI Jakarta |
Lead Sponsor | Collaborator |
---|---|
Indonesia University |
Indonesia,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Proportion of Malassezia spp. from culture examination | Proportion of Malassezia spp. from culture of inflammatory and non-inflammatory facial AV lesions | Sample collected during subjects enrollment | |
Secondary | Proportion of fungal spore load based on microscopic examination | Proportion of fungal spore load of inflammatory and non-inflammatory facial AV lesions based on microscopic examination graded using Jacinto Jamora criteria | Sample collected during subjects enrollment | |
Secondary | Presence and severity of pruritus | Presence and severity of pruritus graded using visual analog scale in correlation with the presence of Malassezia spp and its spore load | Data collected during subjects enrollment |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04321070 -
Bio-equivalence Study With Clinical Endpoints in the Treatment of Acne Vulgaris
|
Phase 1 | |
Recruiting |
NCT05755256 -
The Impact of Probiotics on Skin Hydration in Youth With Mild Acne
|
Phase 2 | |
Completed |
NCT05131373 -
Safety, Tolerability, and Immunogenicity of ORI-A-ce001 for the Treatment of Acne Vulgaris
|
Phase 1 | |
Completed |
NCT01445301 -
Study STF115287, a Clinical Confirmation Study of GSK2585823 in the Treatment of Acne Vulgaris in Japanese Subjects
|
Phase 3 | |
Completed |
NCT03303170 -
Non-Significant Risk Study of Sebacia Microparticles in the Treatment of Facial Acne Vulgaris
|
N/A | |
Completed |
NCT04698239 -
Clinical Evaluation of the Safety and Benefits of the Milesman 445 nm Blue Laser on Inflammatory Acne Lesions.
|
N/A | |
Completed |
NCT02886715 -
A Study Comparing Tazarotene Cream 0.1% to TAZORAC® (Tazarotene) Cream 0.1% and Both to a Placebo Control in the Treatment of Acne Vulgaris
|
Phase 3 | |
Terminated |
NCT02924428 -
Venus Versa Diamondpolar Applicator Treatment Followed by AC Dual Applicator Treatment for Facial Acne Vulgaris
|
N/A | |
Not yet recruiting |
NCT02535871 -
A Study Comparing the Efficacy and Safety of IDP-121 and IDP-121 Vehicle Lotion in the Treatment of Acne Vulgaris
|
Phase 3 | |
Completed |
NCT02709902 -
Study Comparing Adapalene/BP Gel to EPIDUO® FORTE and Both to a Placebo Control in Treatment of Acne Vulgaris
|
Phase 1 | |
Not yet recruiting |
NCT02491060 -
A Study Comparing the Efficacy and Safety of IDP-121 and IDP-121 Vehicle Lotion in the Treatment of Acne Vulgaris
|
Phase 3 | |
Not yet recruiting |
NCT02525822 -
Study to Compare the Safety and Efficacy of IDP-123 Lotion to Tazorac Cream in the Treatment of Acne Vulgaris
|
Phase 2 | |
Completed |
NCT02250430 -
A Phase 1 Study Assessing Local Cutaneous Effects of SB204
|
Phase 1 | |
Completed |
NCT02913001 -
The Effect of a Low Glycemic Load Diet on Hormonal Markers Associated With Acne
|
N/A | |
Completed |
NCT01769664 -
A Study Comparing Clindamycin 1%/Benzoyl Peroxide 5% Topical Gel to Duac® Topical Gel in the Treatment of Acne Vulgaris
|
Phase 1 | |
Completed |
NCT01694810 -
Cutaneous Tolerability and Safety of NVN1000 Topical Gel in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT01727440 -
Identifying the Genetic Predictors of Severe Acne Vulgaris and the Outcome of Oral Isotretinoin Treatment
|
N/A | |
Completed |
NCT01194375 -
A Dose-Ranging Study Evaluating the Safety and Efficacy of IDP-107 in Patients With Acne Vulgaris
|
Phase 2 | |
Completed |
NCT02524665 -
8 Week Study to Evaluate and Compare the Efficacy and Tolerability of MAXCLARITY II and MURAD To Treat Acne
|
Phase 4 | |
Completed |
NCT01706250 -
U0289-401: Eight Week, Split-face, Study to Determine and Compare the Efficacy and Tolerability of MAXCLARITY™ II to PROACTIV™
|
Phase 4 |